Cited by 127Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Alzheimer's disease failed clinical trials

Asher, Shreya, Priefer, Ronny·2022·Life Sciences

DOI 10.1016/j.lfs.2022.120861

Open this paper in CoChat — free account

Abstract

Alzheimer's disease is a progressive neurodegenerative disease typically presenting with symptoms of memory loss and cognitive decline. Existing theories for the causation of this focuses on amyloid beta plaques and neurofibrillary tau tangles. Most US Food and Drug Administration approved therapies for Alzheimer's disease target cognitive function. A multitude of clinical trials, with a variety of different targets have been conducted over the decades which have focused on the two clinical signs, with the only success being the controversial 2021 approval of an IgG1 anti-Ab antibody targeting the clearance of the Aβ plaques. Presented is a review of all previously failed Alzheimer's disease clinical trials and the rationale for their failures.

Integrity signals

Registry

Crossref · 10.1016/j.lfs.2022.120861

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
The Episodic Memory System: Neurocircuitry and Disorders
Dickerson, B. C., & Eichenbaum, H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.126 · Cited by 740
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>
Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628
Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone
Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Fishel, M. A., Kulstad, J. J., Green, P. S., Cook, D. G., et al. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 614
The Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo
Noble, W. J., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J. L., Gaynor, K., LaFrancois, J. J., Wang, L., Kondo, T., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00259-9 · Cited by 511
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Clinical uses of intravenous immunoglobulin
Jolles, S. R. A., Sewell, W. A. C., & Misbah, S. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02834.x · Cited by 374
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., RICHTER, R. W., Soininen, H. S., Thein, S., Shiovitz, T. M., Pilcher, G. D., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease
Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor
May, P. C., Dean, R. A., Lowe, S. L., Martenyi, F., Sheehan, S. M., Boggs, L. N., Monk, S. A., Mathes, B. M., Mergott, D. J., Watson, B. M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3647-11.2011 · Cited by 336
Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease
Fleisher, A., Raman, R., Siemers, E., Becerra, L. M., Clark, C. M., Dean, R. A., Farlow, M. R., Galvin, J. E., Peskind, E. R., Quinn, J. F., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1031 · Cited by 332
Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer’s Disease
Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166876 · Cited by 331
Reasons for failed trials of disease-modifying treatments for alzheimer disease and their contribution in recent research
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330
PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice
Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M. W. N., Azzi, M., Lacombe, D., Kong, X., Aman, A. M., Laurin, J., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.015 · Cited by 313
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Role of RAGE in Alzheimer’s Disease
Cai, Z., Liu, N., Wang, C., Qin, B., Zhou, Y., Xiao, M., Chang, L., Yan, L., & Zhao, B. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0233-3 · Cited by 295
Tramiprosate in mild-to-moderate Alzheimer's disease — a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 291
Developing β‐secretase inhibitors for treatment of Alzheimer’s disease
Ghosh, A. K., Brindisi, M., & Tang, J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07476.x · Cited by 282
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258
Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective
Dunn, B., Stein, P., & Cavazzoni, P. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.4607 · Cited by 246
Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease
TCW, J., & Goate, A. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024539 · Cited by 242
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240
PKC ε Activation Prevents Synaptic Loss, Aβ Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice
Hongpaisan, J., Sun, M., & Alkon, D. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5209-10.2011 · Cited by 231
Neurofibrillary Tangles and Alzheimer’s Disease
Brion, J. (1998) · European Neurology · doi:10.1159/000007969 · Cited by 208
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
Aisen, P. S. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., & Garceau, D. (2006) · Neurology · doi:10.1212/01.wnl.0000244346.08950.64 · Cited by 198
Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
Harrington, C. M., Sawchak, S. T., Chiang, C., Davies, J., Donovan, C., Saunders, A. M., Irizarry, M. C., Jeter, B., Zvartau-Hind, M. E., van Dyck, C. H., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391935 · Cited by 198
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Galasko, D. R., Bell, J. S., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C. H., Thomas, R. G., Aisen, P. S. S., & Study, F. T. A. D. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000364 · Cited by 190
PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease
Sabbagh, M. N., Agro, A., Bell, J. S., Aisen, P. S. S., Schweizer, E. E., & Galasko, D. R. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318204b550 · Cited by 164
A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, N. R., Thomas, R. G., Rissman, R. A., Brewer, J. B., Rafii, M. S., van Dyck, C. H., Jack, C. R., Sano, M., Knopman, D. S., Raman, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003904 · Cited by 157
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease
Menting, K. W., & Claassen, J. A. H. R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00165 · Cited by 144
Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology
Fenili, D., Brown, M., Rappaport, R. V., & McLaurin, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0156-7 · Cited by 136
The Experimental Alzheimer’s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice
Lahiri, D. K., Chen, D., Maloney, B., Holloway, H. W., Yu, Q.-S., Utsuki, T., Giordano, T., Sambamurti, K., & Greig, N. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112102 · Cited by 134
BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Maia, M., & Sousa, E. (2019) · Pharmaceuticals · doi:10.3390/ph12010041 · Cited by 134
Naturally Occurring Autoantibodies against β-Amyloid: Investigating Their Role in Transgenic Animal andIn VitroModels of Alzheimer's Disease
Dodel, R. C., Balakrishnan, K., Keyvani, K., Deuster, O., Neff, F., Andrei‐Selmer, L., Röskam, S., Stüer, C., Al‐Abed, Y., Noelker, C., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4401-10.2011 · Cited by 129
Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals
Galasko, D. R., Graff‐Radford, N. R., May, S. J., Hendrix, S. B., Cottrell, B. A., Sagi, S. A., MATHER, G. G., Laughlin, M. A., Zavitz, K. H., Swabb, E. A., et al. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815d1048 · Cited by 122
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans
Maccecchini, M. L., Chang, M. Y., Pan, C., John, V., Zetterberg, H., & Greig, N. H. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302589 · Cited by 98
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease
Farlow, M. R., Thompson, R. E., Wei, L., Tuchman, A. J., Grenier, E., Crockford, D., Wilke, S., Benison, J., & Alkon, D. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180759 · Cited by 85
Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse
Vohora, D., & Bhowmik, M. (2012) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2012.00072 · Cited by 75
Intravenous immunoglobulin and Alzheimer’s disease: what now?
Loeffler, D. A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-70 · Cited by 52
LRP in Alzheimer’s disease: friend or foe?
Ulery, P. G., & Strickland, D. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11455 · Cited by 42
β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage
Portelius, E., Dean, R. A., Andréasson, U., Mattsson, N., Westerlund, A., Olsson, M., Demattos, R. B., Racke, M. M., Zetterberg, H., May, P. C., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0075-0 · Cited by 38
Inhibition of γ-Secretase Leads to an Increase in Presenilin-1
Sogorb‐Esteve, A., García‐Ayllón, M., Llansola, M., Felipo, V., Blennow, K., & Sáez‐Valero, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0705-1 · Cited by 27
Amino Acid Sequence and Structural Comparison of BACE1 and BACE2 Using Evolutionary Trace Method
Mirsafian, H., Ripen, A. M., Merican, A. F., & Mohamad, S. B. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/482463 · Cited by 23
Acetylcholinesterase Inhibitors for Alzheimer’s disease: Past, Present, and Potential Future
Truong, B., Quiroz, J. A., & Priefer, R. (2020) · Medical Research Archives · doi:10.18103/mra.v8i12.2271 · Cited by 10
Self-citation
Tramiprosate (Alzhemed) for Alzheimer's disease
Malouf, R. S., & Collins, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007549.pub2 · Cited by 3

Research works printed but not linked: 1

Schindowski, 2014, Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations, Degener. Neurol. Neuromuscul. Dis., 4, 121

Sorted by citations

The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death
Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 92
A coupled-GAN architecture to fuse MRI and PET image features for multi-stage classification of Alzheimer’s disease
Choudhury, C., Goel, T., & Tanveer, M. (2024) · Information Fusion · doi:10.1016/j.inffus.2024.102415 · Cited by 52
Neurodegenerative Diseases: Can Caffeine Be a Powerful Ally to Weaken Neuroinflammation?
Ruggiero, M., Calvello, R., Porro, C., Messina, G., Cianciulli, A., & Panaro, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112958 · Cited by 59
Ketogenic diet alleviates cognitive dysfunction and neuroinflammation in APP/PS1 mice via the Nrf2/HO-1 and NF-κB signaling pathways
Jiang, J., Pan, H., Shen, F., Tan, Y., & Chen, S. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373715 · Cited by 50
Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know?
Balistreri, C. R., & Monastero, R. (2023) · Brain Sciences · doi:10.3390/brainsci14010019 · Cited by 47

See all 127

Authors: Asher, S., & Priefer, R.
Affiliations: Massachusetts College of Pharmacy and Health Sciences (US)
Corresponding author: Priefer, Ronny
ORCID: Priefer, Ronny
Venue: Life Sciences
Publisher: Elsevier BV
Published: 2022-10
Volume: 306
Pages: 120861
ISSN: 0024-3205 (ISSN-L)
DOI: 10.1016/j.lfs.2022.120861
OpenAlex: W4289732088
Cited by: 124
References: 61
Citations by year: 2026: 22 · 2025: 31 · 2024: 34 · 2023: 29 · 2022: 8
FWCI: 3.62
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Life Sciences (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, clinical trial failure, amyloid plaques, tau tangles, anti-amyloid therapy, anti-tau therapy, cognitive function, neurodegeneration, therapeutic target
MeSH terms: Alzheimer Disease, Clinical Trials as Topic, Humans, Amyloid beta-Peptides, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer's disease failed clinical trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks